Merck and Moderna's Cancer Vaccine Breakthrough

Scientists have made significant progress in developing an mRNA cancer vaccine after Merck & Co. and Moderna Inc.'s personalized treatment showed promising results in a late-stage trial.

The study, which combined the mRNA-based vaccine intismeran with the immunotherapy Keytruda, demonstrated that it could prevent melanoma from returning in patients.

This milestone marks a critical step forward for cancer vaccines, which have been a long-sought goal for decades. Despite past setbacks and false starts, the technology has finally shown its potential to combat cancer.

Moderna's stock price more than doubled following the news, reflecting investors' excitement about the vaccine's prospects.